Revenue GrowthSugi’s multi-year revenue acceleration (sharp in 2025, positive in 2026) indicates durable demand and successful expansion of pharmacy and front‑end retail sales. Sustainable top-line growth supports scale, stronger purchasing power, and long-term revenue visibility tied to prescription volumes and retail reach.
Improved Cash GenerationA meaningful cash‑flow rebound in 2026 enhances financial flexibility: it supports reinvestment in stores, funds working capital, and creates capacity to service debt or fund strategic initiatives. Better cash conversion also improves resilience to cyclical headwinds versus prior weak years.
Balance Sheet Capacity (Historic)Steady equity and asset growth through 2025 reflect conservative historical capital management and built-up balance‑sheet capacity. That prior conservatism provided optionality to fund expansion or withstand shocks, underpinning long‑term strategic flexibility even as financing needs evolve.